When adverse effects occurred, they were typically mild and transient, with the most common being mild to moderate headaches (similar frequency to placebo groups), minor injection site reactions (redness, slight swelling), and gastrointestinal effects at higher oral doses (nausea, diarrhea)
Individual response varies based on disease severity, concurrent treatments, and overall health status
It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease
Pentadecapeptide BPC 157 and the Central Nervous System
For more information on this product please see the patient information leaflet via the link below Before attending your appointment, it is preferred that you have a recent blood test to check your B12 level